IP Library › Granted Patent US 10,624,862
Granted Patent B2
US 10,624,862 · App. 14/327,671 · Granted Apr 21, 2020

Tamper-resistant dosage form containing ethylene-vinyl acetate polymer

Inventors: Klaus Wening (Köln, DE); Lutz Barnscheid (Mönchengladbach, DE); Sebastian Schwier (Aachen, DE); Anja Geißler (Stolberg, DE)
Assignee: GRÜNENTHAL GMBH
A61K31/135A61K9/146A61K9/1635A61K9/2031A61K31/137B29C51/002B29C48/0011B29C48/05B29K2023/083B29K2105/0085
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,862
App. No.
14/327,671
Granted
Apr 21, 2020
Kind
B2
Abstract

The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.

Claims (16)

1. A tamper-resistant, oral pharmaceutical dosage form comprising a homogeneous mixture of: (A) a pharmacologically active ingredient having psychotropic action and (B) a prolonged release matrix comprising 55 to 80 wt.-% relative to a total weight of the dosage form of an ethylene-vinyl acetate (EVA) polymer, wherein the EVA polymer provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.

2. The pharmaceutical dosage form according to claim 1 , wherein the EVA polymer comprises repetition units derived from ethylene and vinyl acetate and/or vinyl alcohol.

3. The pharmaceutical dosage form according to claim 1 , wherein the EVA polymer contains at least 50 wt.-% of ethylene repetition units, relative to the total weight of the EVA polymer.

4. The pharmaceutical dosage form according to claim 3 , wherein the EVA polymer contains from 50 to 95 wt.-% of ethylene repetition units, relative to the total weight of the EVA polymer.

5. The pharmaceutical dosage form according to claim 1 , wherein the EVA polymer has a melt flow rate at 190° C. and 2.16 kg within the range of from 1 to 160 g/10 min measured according to ASTM D1238.

6. The pharmaceutical dosage form according to claim 1 , which is monolithic and has a breaking strength of at least 300 N.

7. The pharmaceutical dosage form according to claim 1 , which is monolithic and has an extension in any direction of at least 2.0 mm.

8. The pharmaceutical dosage form according to claim 1 , wherein the pharmacologically active ingredient is an opioid or a physiologically acceptable salt thereof.

9. The pharmaceutical dosage form according to claim 1 , which is hot-melt extruded.

10. A process for the production of the tamper-resistant, oral pharmaceutical dosage form according to claim 1 , said process comprising the steps of:

(i) mixing a pharmacologically active ingredient, 55 to 80 wt.-% relative to a total weight of the dosage form of an ethylene-vinyl acetate (EVA) polymer, and optionally further excipients to form a mixture; and

(ii) thermoforming the mixture obtained in step (i), wherein said mixture is simultaneously or before or after the application of heat subjected to pressure.

11. A tamper-resistant, oral pharmaceutical dosage form obtained by the process according to claim 10 .

12. A method of treating pain in a patient, said method comprising administering to said patient a dosage form according to claim 1 wherein the pharmacologically active ingredient is an opioid or a physiologically acceptable salt thereof.

13. The pharmaceutical dosage form according to claim 1 , which is multiparticulate, wherein at least a fraction of individual particles have a breaking strength of at least 300 N.

14. The pharmaceutical dosage form according to claim 1 , which is multiparticulate, wherein individual drug-containing particles have an extension in any direction of at least 2.0 mm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2014
From: WENING, KLAUS, DR.; BARNSCHEID, LUTZ, DR.; SCHWIER, SEBASTIAN, DR.; GEISSLER, ANJA
To: GRÜNENTHAL GMBH
Reel/Frame 033484/0496 →
Priority Claims (1)
EP 13176303 · Jul 12, 2013 · regional
Continuity (1)
Related Publication 20150017250A1 · Jan 15, 2015
Cited By (2)
US 12,472,148 US 12,502,360